JP2016536322A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536322A5 JP2016536322A5 JP2016532264A JP2016532264A JP2016536322A5 JP 2016536322 A5 JP2016536322 A5 JP 2016536322A5 JP 2016532264 A JP2016532264 A JP 2016532264A JP 2016532264 A JP2016532264 A JP 2016532264A JP 2016536322 A5 JP2016536322 A5 JP 2016536322A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody variable
- chain domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 74
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 33
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 108091008324 binding proteins Proteins 0.000 claims description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 4
- 239000012636 effector Substances 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 101100334515 Homo sapiens FCGR3A gene Proteins 0.000 claims 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
Images
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13179630 | 2013-08-07 | ||
| EP13179630.2 | 2013-08-07 | ||
| EP13189599 | 2013-10-21 | ||
| EP13189599.7 | 2013-10-21 | ||
| PCT/EP2014/002177 WO2015018527A1 (en) | 2013-08-07 | 2014-08-07 | ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016536322A JP2016536322A (ja) | 2016-11-24 |
| JP2016536322A5 true JP2016536322A5 (enExample) | 2017-09-07 |
| JP6529498B2 JP6529498B2 (ja) | 2019-06-12 |
Family
ID=51453717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532264A Active JP6529498B2 (ja) | 2013-08-07 | 2014-08-07 | ＥＧＦＲｖＩＩＩに対して特異的な抗体結合部位 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10273309B2 (enExample) |
| EP (1) | EP3030581B1 (enExample) |
| JP (1) | JP6529498B2 (enExample) |
| CN (1) | CN105555804B (enExample) |
| AU (1) | AU2014304930B2 (enExample) |
| CA (1) | CA2920173C (enExample) |
| DK (1) | DK3030581T3 (enExample) |
| HR (1) | HRP20210561T1 (enExample) |
| HU (1) | HUE054057T2 (enExample) |
| LT (1) | LT3030581T (enExample) |
| RU (1) | RU2696892C2 (enExample) |
| SI (1) | SI3030581T1 (enExample) |
| WO (1) | WO2015018527A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY178160A (en) * | 2014-03-11 | 2020-10-06 | Regeneron Pharma | Anti-egfrviii antibodies and uses thereof |
| US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| EP2982693A1 (en) | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| CN107108735B (zh) * | 2014-11-25 | 2021-05-04 | 药物抗体公司 | 新型egfrviii抗体和包含所述抗体的组合物 |
| EP4190814A1 (en) | 2015-05-29 | 2023-06-07 | Amphivena Therapeutics, Inc. | Methods of using bispecific cd33 and cd3 binding proteins |
| EP3307319A4 (en) | 2015-06-09 | 2019-05-22 | Memorial Sloan Kettering Cancer Center | T CELL RECEPTOR-SIMILAR ANTIBODIES SPECIFIC TO PEPTID OF THE LATENT EBV MEMBRANE PROTEIN 2A PRESENTED BY HUMAN HLA |
| WO2016204966A1 (en) * | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI744242B (zh) * | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| EP3405481B1 (en) | 2016-01-21 | 2023-01-18 | Pfizer Inc. | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii |
| CN109219618B (zh) * | 2016-01-21 | 2022-08-09 | 辉瑞大药厂 | 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途 |
| CA3011942A1 (en) | 2016-02-03 | 2017-08-10 | Amgen Research (Munich) Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs |
| CN107556386A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用 |
| RU2721582C1 (ru) * | 2016-08-05 | 2020-05-20 | И-Байолоджикс Инк. | Антитела против лиганда-1 запрограммированной смерти (PD-L1) и их применение |
| AU2017306506B2 (en) | 2016-08-05 | 2020-05-21 | Y-Biologics Inc. | Antibody to programmed cell death 1 (PD-1) and use thereof |
| CN106501518A (zh) * | 2017-01-06 | 2017-03-15 | 北京弘润天源生物技术股份有限公司 | 一种检测EGFRvⅢ的免疫组化抗体试剂及检测方法 |
| CA3051062C (en) * | 2017-02-28 | 2023-09-26 | Affimed Gmbh | Tandem diabody for cd16a-directed nk-cell engagement |
| AR115360A1 (es) | 2018-02-08 | 2021-01-13 | Genentech Inc | Moléculas de unión al antígeno y métodos de uso |
| KR102924742B1 (ko) * | 2018-03-14 | 2026-02-10 | 아피메트 게엠베하 | 이중특이적 egfr/cd16 항원-결합 단백질 |
| CN118271445A (zh) * | 2018-12-21 | 2024-07-02 | 豪夫迈·罗氏有限公司 | 与cd3结合的抗体 |
| AU2020208110A1 (en) * | 2019-01-14 | 2021-07-15 | Nanjing Legend Biotech Co., Ltd. | Chimeric receptor polypeptides and uses thereof |
| BR112022011357A2 (pt) | 2019-12-13 | 2022-08-23 | Genentech Inc | Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo |
| WO2022002033A1 (zh) * | 2020-06-30 | 2022-01-06 | 和铂医药(上海)有限责任公司 | 具有H2L2与HCAb结构的结合蛋白 |
| US20240101646A1 (en) * | 2021-01-22 | 2024-03-28 | Vanderbilt University | Sars-cov-2 coronavirus antibodies and uses thereof |
| KR20240007171A (ko) | 2021-05-14 | 2024-01-16 | 제넨테크, 인크. | 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법 |
| EP4370557A4 (en) * | 2021-07-16 | 2025-10-01 | Medical Guidance Systems Llc | TAX-INTERACTING PROTEIN-BINDING MOLECULES 1 (TIP1) |
| CN116375868A (zh) * | 2021-12-31 | 2023-07-04 | 康源博创生物科技(北京)有限公司 | 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用 |
| TW202506733A (zh) | 2023-06-12 | 2025-02-16 | 美商安進公司 | 淋巴毒素β受體促效劑結合蛋白 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19819846B4 (de) * | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| PL357448A1 (en) * | 2000-02-25 | 2004-07-26 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services | Anti-egfrviii scfvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof |
| US20100056762A1 (en) * | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| US7736644B2 (en) * | 2003-06-27 | 2010-06-15 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
-
2014
- 2014-08-07 HU HUE14758087A patent/HUE054057T2/hu unknown
- 2014-08-07 DK DK14758087.2T patent/DK3030581T3/da active
- 2014-08-07 WO PCT/EP2014/002177 patent/WO2015018527A1/en not_active Ceased
- 2014-08-07 RU RU2016106577A patent/RU2696892C2/ru active
- 2014-08-07 CN CN201480045405.5A patent/CN105555804B/zh active Active
- 2014-08-07 JP JP2016532264A patent/JP6529498B2/ja active Active
- 2014-08-07 AU AU2014304930A patent/AU2014304930B2/en active Active
- 2014-08-07 LT LTEP14758087.2T patent/LT3030581T/lt unknown
- 2014-08-07 CA CA2920173A patent/CA2920173C/en active Active
- 2014-08-07 EP EP14758087.2A patent/EP3030581B1/en active Active
- 2014-08-07 HR HRP20210561TT patent/HRP20210561T1/hr unknown
- 2014-08-07 SI SI201431808T patent/SI3030581T1/sl unknown
-
2016
- 2016-02-04 US US15/015,261 patent/US10273309B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529067A5 (enExample) | ||
| RU2016106577A (ru) | САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII | |
| JP2019525738A5 (enExample) | ||
| JP2017504578A5 (enExample) | ||
| JP2020517287A5 (enExample) | ||
| JP2014158485A5 (enExample) | ||
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| JP2020519643A5 (enExample) | ||
| JP2020525032A5 (enExample) | ||
| RU2018146050A (ru) | Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген | |
| JP2020510659A5 (enExample) | ||
| AR108066A1 (es) | Receptores quiméricos para cll-1 y métodos de uso de los mismos | |
| FI4050034T3 (fi) | Cd3:een sitoutuvia vasta-aineita | |
| PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| JP2019500862A5 (enExample) | ||
| JP2018532766A5 (enExample) | ||
| FI3525583T3 (fi) | Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä | |
| JP2018517431A5 (enExample) | ||
| JP2020500510A5 (enExample) | ||
| PE20190120A1 (es) | Moleculas de union a bcma y metodos de uso de las mismas | |
| JP2019501883A5 (enExample) | ||
| RU2016151265A (ru) | Антитела, направленные на cd127 | |
| JP2018521638A5 (enExample) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| RU2017105120A (ru) | Cd3-связывающий домен |